Published in PLoS One on January 15, 2013
Integrative analysis of multi-omics data for identifying multi-markers for diagnosing pancreatic cancer. BMC Genomics (2015) 1.44
MicroRNAs: novel players in cancer diagnosis and therapies. Biomed Res Int (2014) 1.05
MicroRNAs as emerging biomarkers and therapeutic targets for pancreatic cancer. World J Gastroenterol (2014) 0.98
MicroRNAs in pancreatic malignancy: progress and promises. Cancer Lett (2014) 0.98
Let-7b expression determines response to chemotherapy through the regulation of cyclin D1 in glioblastoma. J Exp Clin Cancer Res (2013) 0.98
Molecular mechanisms underlying the role of microRNAs in the chemoresistance of pancreatic cancer. Biomed Res Int (2014) 0.90
Using Drosophila melanogaster to identify chemotherapy toxicity genes. Genetics (2014) 0.87
A p53 drug response signature identifies prognostic genes in high-risk neuroblastoma. PLoS One (2013) 0.85
The LIN28/let-7 Pathway in Cancer. Front Genet (2017) 0.79
Differential Expression of MicroRNAs in Tissues and Plasma Co-exists as a Biomarker for Pancreatic Cancer. J Cancer Sci Ther (2016) 0.78
Circulating microRNAs and long non-coding RNAs in gastric cancer diagnosis: An update and review. World J Gastroenterol (2015) 0.78
A Potent Chemotherapeutic Strategy with Eg5 Inhibitor against Gemcitabine Resistant Bladder Cancer. PLoS One (2015) 0.78
Inhibition of S-Adenosylmethionine-Dependent Methyltransferase Attenuates TGFβ1-Induced EMT and Metastasis in Pancreatic Cancer: Putative Roles of miR-663a and miR-4787-5p. Mol Cancer Res (2016) 0.78
Identification of miR-145 targets through an integrated omics analysis. Mol Biosyst (2014) 0.77
Evaluation of 9-cis retinoic acid and mitotane as antitumoral agents in an adrenocortical xenograft model. Am J Cancer Res (2015) 0.77
Molecular Drivers of Pancreatic Cancer Pathogenesis: Looking Inward to Move Forward. Int J Mol Sci (2017) 0.75
Regulation of multidrug resistance by microRNAs in anti-cancer therapy. Acta Pharm Sin B (2016) 0.75
Cell cycle dependent RRM2 may serve as proliferation marker and pharmaceutical target in adrenocortical cancer. Am J Cancer Res (2016) 0.75
Influence of microRNAs and Long Non-Coding RNAs in Cancer Chemoresistance. Genes (Basel) (2017) 0.75
Gambogic acid sensitizes gemcitabine efficacy in pancreatic cancer by reducing the expression of ribonucleotide reductase subunit-M2 (RRM2). J Exp Clin Cancer Res (2017) 0.75
SET contributes to the epithelial-mesenchymal transition of pancreatic cancer. Oncotarget (2017) 0.75
miR-202 Diminishes TGFbeta Receptors and Attenuates TGFbeta1-induced EMT in Pancreatic Cancer. Mol Cancer Res (2017) 0.75
MicroRNA expression profiles classify human cancers. Nature (2005) 69.12
Switching from repression to activation: microRNAs can up-regulate translation. Science (2007) 17.00
Extensive post-transcriptional regulation of microRNAs and its implications for cancer. Genes Dev (2006) 11.04
The let-7 microRNA represses cell proliferation pathways in human cells. Cancer Res (2007) 9.32
The let-7 family of microRNAs. Trends Cell Biol (2008) 6.24
Targeting microRNAs in cancer: rationale, strategies and challenges. Nat Rev Drug Discov (2010) 6.07
Up-regulation of miR-200 and let-7 by natural agents leads to the reversal of epithelial-to-mesenchymal transition in gemcitabine-resistant pancreatic cancer cells. Cancer Res (2009) 4.24
MicroRNAs in development and disease. Physiol Rev (2011) 4.13
Lin28: A microRNA regulator with a macro role. Cell (2010) 3.39
The human let-7a-3 locus contains an epigenetically regulated microRNA gene with oncogenic function. Cancer Res (2007) 2.54
Hypermethylation of let-7a-3 in epithelial ovarian cancer is associated with low insulin-like growth factor-II expression and favorable prognosis. Cancer Res (2007) 2.45
Antagonistic role of hnRNP A1 and KSRP in the regulation of let-7a biogenesis. Nat Struct Mol Biol (2010) 2.30
Pancreatic cancer: understanding and overcoming chemoresistance. Nat Rev Gastroenterol Hepatol (2010) 2.15
Determinants of resistance to 2',2'-difluorodeoxycytidine (gemcitabine). Drug Resist Updat (2002) 1.91
MicroRNA let-7: an emerging next-generation cancer therapeutic. Curr Oncol (2010) 1.90
Controlled protein degradation regulates ribonucleotide reductase activity in proliferating mammalian cells during the normal cell cycle and in response to DNA damage and replication blocks. J Biol Chem (2000) 1.87
Gemcitabine chemoresistance and molecular markers associated with gemcitabine transport and metabolism in human pancreatic cancer cells. Br J Cancer (2007) 1.87
Lin28-let7 modulates radiosensitivity of human cancer cells with activation of K-Ras. Int J Radiat Oncol Biol Phys (2010) 1.85
Mouse ribonucleotide reductase R2 protein: a new target for anaphase-promoting complex-Cdh1-mediated proteolysis. Proc Natl Acad Sci U S A (2003) 1.77
RNA interference targeting the M2 subunit of ribonucleotide reductase enhances pancreatic adenocarcinoma chemosensitivity to gemcitabine. Oncogene (2004) 1.70
Overexpression of the R2 subunit of ribonucleotide reductase in human nasopharyngeal cancer cells reduces radiosensitivity. Cancer J (2003) 1.69
let-7 Overexpression leads to an increased fraction of cells in G2/M, direct down-regulation of Cdc34, and stabilization of Wee1 kinase in primary fibroblasts. J Biol Chem (2009) 1.65
Overexpression of ribonucleotide reductase as a mechanism of resistance to 2,2-difluorodeoxycytidine in the human KB cancer cell line. Cancer Res (1999) 1.62
Tumor engraftment in nude mice and enrichment in stroma- related gene pathways predict poor survival and resistance to gemcitabine in patients with pancreatic cancer. Clin Cancer Res (2011) 1.59
let-7 MicroRNA transfer in pancreatic cancer-derived cells inhibits in vitro cell proliferation but fails to alter tumor progression. Hum Gene Ther (2009) 1.58
LIN-28 co-transcriptionally binds primary let-7 to regulate miRNA maturation in Caenorhabditis elegans. Nat Struct Mol Biol (2011) 1.51
Resistance of pancreatic cancer to gemcitabine treatment is dependent on mitochondria-mediated apoptosis. Int J Cancer (2004) 1.43
Functional analysis of microRNAs in human hepatocellular cancer stem cells. J Cell Mol Med (2012) 1.35
Let-7d functions as novel regulator of epithelial-mesenchymal transition and chemoresistant property in oral cancer. Oncol Rep (2011) 1.34
Analysis of ribonucleotide reductase M2 mRNA levels in patient samples after GTI-2040 antisense drug treatment. Oncol Rep (2006) 1.32
Implication of checkpoint kinase-dependent up-regulation of ribonucleotide reductase R2 in DNA damage response. J Biol Chem (2009) 1.31
The human ribonucleotide reductase subunit hRRM2 complements p53R2 in response to UV-induced DNA repair in cells with mutant p53. Cancer Res (2003) 1.28
Let-7 modulates acquired resistance of ovarian cancer to Taxanes via IMP-1-mediated stabilization of multidrug resistance 1. Int J Cancer (2011) 1.27
S Phase-specific transcription of the mouse ribonucleotide reductase R2 gene requires both a proximal repressive E2F-binding site and an upstream promoter activating region. J Biol Chem (2003) 1.27
Clinical pharmacology and pharmacogenetics of gemcitabine. Drug Metab Rev (2009) 1.27
Targeting SET/I(2)PP2A oncoprotein functions as a multi-pathway strategy for cancer therapy. Oncogene (2011) 1.26
Overexpression of neuropilin-1 promotes constitutive MAPK signalling and chemoresistance in pancreatic cancer cells. Br J Cancer (2005) 1.22
Recent developments in palliative chemotherapy for locally advanced and metastatic pancreas cancer. World J Gastroenterol (2010) 1.20
The potential functions of primary microRNAs in target recognition and repression. EMBO J (2010) 1.13
Ribonucleotide reductase subunit M2 mRNA expression in pretreatment biopsies obtained from unresectable pancreatic carcinomas. J Gastroenterol (2007) 1.10
CNT1 expression influences proliferation and chemosensitivity in drug-resistant pancreatic cancer cells. Cancer Res (2011) 1.06
Molecular mechanisms underlying the role of microRNAs (miRNAs) in anticancer drug resistance and implications for clinical practice. Crit Rev Oncol Hematol (2011) 1.04
The translational regulator eIF3a: the tricky eIF3 subunit! Biochim Biophys Acta (2010) 1.02
Overcoming nucleoside analog chemoresistance of pancreatic cancer: a therapeutic challenge. Cancer Lett (2012) 1.00
Expression and hepatobiliary transport characteristics of the concentrative and equilibrative nucleoside transporters in sandwich-cultured human hepatocytes. Am J Physiol Gastrointest Liver Physiol (2008) 1.00
RNA interference demonstrates a novel role for integrin-linked kinase as a determinant of pancreatic adenocarcinoma cell gemcitabine chemoresistance. Clin Cancer Res (2005) 1.00
Human ribonucleotide reductase M2 subunit gene amplification and transcriptional regulation in a homogeneous staining chromosome region responsible for the mechanism of drug resistance. Cytogenet Cell Genet (2001) 0.98
Expression of multidrug resistance-associated protein 2 is involved in chemotherapy resistance in human pancreatic cancer. Int J Oncol (2008) 0.96
Nuclear factor Y regulation and promoter transactivation of human ribonucleotide reductase subunit M2 gene in a Gemcitabine resistant KB clone. Biochem Pharmacol (2004) 0.87
c-Myc initiates illegitimate replication of the ribonucleotide reductase R2 gene. Oncogene (2002) 0.82
A microRNA polycistron as a potential human oncogene. Nature (2005) 40.21
Argonaute2 is the catalytic engine of mammalian RNAi. Science (2004) 22.86
The role of microRNA-1 and microRNA-133 in skeletal muscle proliferation and differentiation. Nat Genet (2005) 17.07
MicroRNAs regulate brain morphogenesis in zebrafish. Science (2005) 11.16
Lin-28 interaction with the Let-7 precursor loop mediates regulated microRNA processing. RNA (2008) 6.86
Direct regulation of an oncogenic micro-RNA cluster by E2F transcription factors. J Biol Chem (2006) 4.57
Transgenic over-expression of the microRNA miR-17-92 cluster promotes proliferation and inhibits differentiation of lung epithelial progenitor cells. Dev Biol (2007) 4.16
Expression of microRNAs is dynamically regulated during cardiomyocyte hypertrophy. J Mol Cell Cardiol (2007) 3.67
microRNA expression in the prefrontal cortex of individuals with schizophrenia and schizoaffective disorder. Genome Biol (2007) 3.26
Planetary biology--paleontological, geological, and molecular histories of life. Science (2002) 2.21
Cancer--an ayurvedic perspective. Pharmacol Res (2005) 2.03
Inferring the palaeoenvironment of ancient bacteria on the basis of resurrected proteins. Nature (2003) 1.75
miR-17~92 cooperates with RB pathway mutations to promote retinoblastoma. Genes Dev (2011) 1.66
Fgf-dependent depletion of microRNA-133 promotes appendage regeneration in zebrafish. Genes Dev (2008) 1.64
Profiling gene expression in human placentae of different gestational ages: an OPRU Network and UW SCOR Study. Reprod Sci (2008) 1.25
Toxoplasma gondii infection specifically increases the levels of key host microRNAs. PLoS One (2010) 1.22
New insights into the pharmacology and cytotoxicity of gemcitabine and 2',2'-difluorodeoxyuridine. Mol Cancer Ther (2008) 1.11
CNT1 expression influences proliferation and chemosensitivity in drug-resistant pancreatic cancer cells. Cancer Res (2011) 1.06
PpATG9 encodes a novel membrane protein that traffics to vacuolar membranes, which sequester peroxisomes during pexophagy in Pichia pastoris. Mol Biol Cell (2005) 1.03
Overcoming nucleoside analog chemoresistance of pancreatic cancer: a therapeutic challenge. Cancer Lett (2012) 1.00
The role of the equilibrative nucleoside transporter 1 (ENT1) in transport and metabolism of ribavirin by human and wild-type or Ent1-/- mouse erythrocytes. J Pharmacol Exp Ther (2009) 0.97
Human equilibrative nucleoside transporter-3 (hENT3) spectrum disorder mutations impair nucleoside transport, protein localization, and stability. J Biol Chem (2010) 0.94
Up-regulation of vitamin B1 homeostasis genes in breast cancer. J Nutr Biochem (2013) 0.89
Transcriptional suppression, DNA methylation, and histone deacetylation of the regulator of G-protein signaling 10 (RGS10) gene in ovarian cancer cells. PLoS One (2013) 0.86
A mild form of SLC29A3 disorder: a frameshift deletion leads to the paradoxical translation of an otherwise noncoding mRNA splice variant. PLoS One (2012) 0.85
The role of nucleoside transporters in the erythrocyte disposition and oral absorption of ribavirin in the wild-type and equilibrative nucleoside transporter 1-/- mice. J Pharmacol Exp Ther (2009) 0.84
Malignant transformation of colonic epithelial cells by a colon-derived long noncoding RNA. Biochem Biophys Res Commun (2013) 0.84
Pharmacological reversal of histone methylation presensitizes pancreatic cancer cells to nucleoside drugs: in vitro optimization and novel nanoparticle delivery studies. PLoS One (2013) 0.83
Early and late molecular events of glucose-induced pexophagy in Pichia pastoris require Vac8. Autophagy (2006) 0.82
Characterization of a new antibody raised against the NH2 terminus of P-glycoprotein. Clin Cancer Res (2005) 0.80
2'-Fluoro-6'-methylene-carbocyclic adenosine phosphoramidate (FMCAP) prodrug: in vitro anti-HBV activity against the lamivudine-entecavir resistant triple mutant and its mechanism of action. Bioorg Med Chem Lett (2012) 0.78
Antiviral activity of novel 2'-fluoro-6'-methylene-carbocyclic adenosine against wild-type and drug-resistant hepatitis B virus mutants. Bioorg Med Chem Lett (2011) 0.77
Ayurvedic drug discovery. Expert Opin Drug Discov (2007) 0.75